News Releases

TapImmune To Present At Biotech Showcase 2017

JACKSONVILLE, Fla., Jan. 5, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today announced its Chairman and CEO, Dr. Glynn Wilson, will present at Biotech Showcase 2017 to be held January 9-11, 2017, at the Hilton San Francisco Union Square.

Details of the presentation are as follows:


Biotech Showcase 2017


Tuesday, January 10, 2017


9:00 a.m. (Pacific Time)


Hilton San Francisco Union Square

The webcast of the presentation can be viewed live and will be available for three months after the event by clicking on the following link:  

About TapImmune, Inc.
TapImmune, Inc. is an immuno-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.

Please visit the company's website at for more details. 

Forward-Looking Statement Disclaimer 
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at The Company assumes no obligation to update the forward-looking statements.


SOURCE TapImmune, Inc.

For further information: TapImmune, Inc., Glynn Wilson, Ph.D., Chairman & CEO, (866)-359-7541